Perspective Therapeutics/$CATX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perspective Therapeutics
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Ticker
$CATX
Sector
Health
Primary listing
AMEX
Employees
139
Headquarters
CATX Metrics
BasicAdvanced
$276M
-
-$1.21
1.19
-
Price and volume
Market cap
$276M
Beta
1.19
52-week high
$16.55
52-week low
$1.60
Average daily volume
861K
Financial strength
Current ratio
17.016
Quick ratio
16.703
Long term debt to equity
0.978
Total debt to equity
1.341
Interest coverage (TTM)
-514.45%
Profitability
EBITDA (TTM)
-72.949
Gross margin (TTM)
-3,005.03%
Net profit margin (TTM)
-5,790.07%
Operating margin (TTM)
-5,140.99%
Effective tax rate (TTM)
2.42%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-15.56%
Return on equity (TTM)
-32.92%
Valuation
Price to revenue (TTM)
177.371
Price to book
0.97
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-2.515
Free cash flow yield (TTM)
-39.75%
Free cash flow per share (TTM)
-1.479
Growth
Revenue change (TTM)
-3.60%
Earnings per share change (TTM)
-30.52%
What the Analysts think about CATX
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
CATX Financial Performance
Revenues and expenses
CATX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Perspective Therapeutics stock?
Perspective Therapeutics (CATX) has a market cap of $276M as of August 13, 2025.
What is the P/E ratio for Perspective Therapeutics stock?
The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of August 13, 2025.
Does Perspective Therapeutics stock pay dividends?
No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of August 13, 2025.
When is the next Perspective Therapeutics dividend payment date?
Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.
What is the beta indicator for Perspective Therapeutics?
Perspective Therapeutics (CATX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.